United Biopharma Gets Taiwan Fda Nod For Phase 2 Ind For Ub-221 To Treat Chronic Spontaneous Urticaria
United Biopharma (Ubp), A Taiwan-Based Late Clinical-Stage Biopharmaceutical Company, Has Announced The Approval Of A Phase 2 Clinical Trial With Novel Anti-Ige Monoclonal Antibody Ub-221 By The Taiwan Food And Drug Administration (Tfda).This Phase 2 Clinical Trial (Double-Blind, Placebo-Controlled) Aims To Evaluate The Efficacy Of Ub-221 As A Long-Acting Add-On Therapy For Treatment Of Chronic Spontaneous Urticaria (Csu) And Provide Evidence Of The Therapeutic Potential Of Two High-Dose Ub-221 Treatments Over A 6-Month Period.Spontaneous Urticaria Is Categorized Into Acute ( Six Weeks) Variants. With An Incidence Rate Of 0.5
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
